Chaperone mediated autophagy
Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.* P < .05 vs control without siRNA † P < .05, compared with control. All experiments were performed in triplicate. F, Typical examples of the Western blots analyzing A53T α-synuclein turnover during 48 hours under normal conditions (top) or in the presence of LAMP2A siRNA (middle) or 3-MA (bottom). E, Analysis of A53T α-synuclein half-life under control conditions or under conditions inhibiting proteasomal (PSI), chaperone-mediated autophagy (LAMP2A siRNA), macroautophagy (3-MA), or lysosomal (NH 4Cl) function. Both C and D were acquired under identical conditions to compare the staining intensity. D, Immunofluorescence staining of WT α-synuclein SH-SY5Y cells after LAMP2A depletion demonstrating increased α-synuclein content in the cytoplasmic and perinuclear regions.
![chaperone mediated autophagy chaperone mediated autophagy](http://www.anti-agingfirewalls.com/__oneclick_uploads/2013/04/kindsofautophagy1.jpg)
C, Immunofluorescence staining of WT α-synuclein SH-SY5Y cells (green anti–α-synuclein antibody blue, nuclear DAPI) under normal conditions. B, Typical examples of the Western blots analyzing α-synuclein turnover during 48 hours under normal conditions (top) or in the presence of LAMP2A siRNA (middle) or 3-MA and LAMP2A siRNA (bottom). Influence of chaperone-mediated autophagy inhibition (plus siRNA) upon WT α-synuclein half-life and when combined with impaired UPS (PSI), macroautophagy (3-MA), or lysosomal function (ammonium chloride ). A, Wild-type α-synuclein half-life under control conditions and after chaperone-mediated autophagy (lysosomal-associated membrane protein 2A small interfering RNA ), ubiquitin-dependent proteasomal system (UPS) (benzyloxycarbonyl- L-isoleucyl-γ-t-butyl- L-glutamyl- L-alanyl-leucinal ), macroautophagy (3-methyladenine ), or lysosomal (NH 4Cl) inhibition. Degradation pathways of wild-type (WT) α-synuclein.